Drug Trial Radar · NCT04308681
A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis
Last checked: Nov 19, 2026Latest source record: Feb 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
403
Actual
Start
Jul 29, 2020
Primary completion
Aug 4, 2022
Study completion Sep 22, 2023
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Mar 16, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to provide an initial evaluation of the effectiveness of BMS-986278 in participants with lung fibrosis, to demonstrate the safety of BMS-986278, and provide information on the drug levels of BMS-986278 in these participants.
Conditions
- Pulmonary Fibrosis
Interventions
BMS-986278 PlaceboOther
Specified Dose on Specified Days
BMS-986278Drug
Specified Dose on Specified Days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Percent Predicted Forced Vital Capacity (ppFVC) in IPF ParticipantsTime frame: From baseline (first dose) up to week 26
Locations
119 sites in 18 countries. Site status is shown where the registry gives one.
Local Institution - 0032
Birmingham, Alabama
Local Institution
Phoenix, Arizona
Local Institution - 0028
Los Angeles, California
Local Institution - 0043
Stanford, California
University of Colorado Anschutz Medical Campus-Department of Medicine
Aurora, Colorado
Local Institution - 0006
Denver, Colorado
Local Institution - 0171
New Haven, Connecticut
Local Institution - 0035
Gainesville, Florida
Local Institution - 0166
Orlando, Florida
Local Institution - 0078
Atlanta, Georgia
Local Institution - 0031
Kansas City, Kansas
Local Institution - 0154
Baltimore, Maryland
Local Institution - 0003
Boston, Massachusetts
Local Institution - 0030
Chesterfield, Missouri
Local Institution - 0036
St Louis, Missouri
Local Institution - 0029
Cincinnati, Ohio
Local Institution - 0164
Columbus, Ohio
Local Institution
Hershey, Pennsylvania
Local Institution
Nashville, Tennessee
Local Institution - 0096
Charlottesville, Virginia
Local Institution
Falls Church, Virginia
Local Institution - 0115
Buenos Aires, Argentina
Local Institution - 0048
Buenos Aires, Argentina
Local Institution - 0122
Mendoza, Argentina
Local Institution - 0049
Buenos Aires, Distrito Federal, Argentina
Local Institution - 0103
Rosario, Santa Fe Province, Argentina
Local Institution - 0097
San Miguel de Tucumán, Tucumán Province, Argentina
Local Institution - 0045
Camperdown, New South Wales, Australia
Local Institution - 0025
Westmead, New South Wales, Australia
Local Institution - 0026
Brisbane, Queensland, Australia
Local Institution - 0046
Greenslopes, Queensland, Australia
Local Institution - 0022
Adelaide, South Australia, Australia
Local Institution - 0023
Heidelberg, Victoria, Australia
Local Institution - 0021
Murdoch, Western Australia, Australia
Local Institution - 0044
Nedlands, Western Australia, Australia
Local Institution - 0074
Brussels, Belgium
Local Institution - 0065
Leuven, Belgium
Local Institution - 0051
Liège, Belgium
Local Institution - 0076
São Paulo, Brazil
Local Institution
Porto Alegre, Rio Grande do Sul, Brazil
Showing 40 of 119 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.